Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of the neck in the setting of definitive chemoradiation: is there a consensus? A GETTEC study.
Thariat J, Hamoir M, Garrel R, Cosmidis A, Dassonville O, Janot, Righini CA, Vedrine PO, Prades JM, Lacau-Saint-Guily J, Jegoux F, Malard O, De Mones E, Benlyazid A, Bensadoun RJ, Baujat B, Merol JC, Ferron C, Scavennec C, Salvan D, Mallet Y, Moriniere S, Vergez S, Choussy O, Dollivet G, Guevara N, Ceruse P, De Raucourt D, Lallemant B, Lawson G, Lindas P, Poupart M, Duflo S, Dufour X. Thariat J, et al. Among authors: poupart m. Ann Surg Oncol. 2012 Jul;19(7):2311-9. doi: 10.1245/s10434-012-2275-9. Epub 2012 Mar 9. Ann Surg Oncol. 2012. PMID: 22402813 Clinical Trial.
T1-T2 NO oropharyngeal cancers treated with surgery alone. A GETTEC study.
Cosmidis A, Rame JP, Dassonville O, Temam S, Massip F, Poissonnet G, Poupart M, Marandas P, De Raucourt D; Groupement d'Etudes des Tumeurs de la Tête et du Cou (GETTEC). Cosmidis A, et al. Among authors: poupart m. Eur Arch Otorhinolaryngol. 2004 May;261(5):276-81. doi: 10.1007/s00405-003-0694-8. Epub 2003 Oct 9. Eur Arch Otorhinolaryngol. 2004. PMID: 14551793
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Céruse P, Cosmidis A, Belot A, Rabilloud M, Fuchsmann C, Poupart M, Ramade A, Tartas S, Favrel V, Pommier P, Zrounba P, Fayette J. Céruse P, et al. Among authors: poupart m. Anticancer Drugs. 2014 Sep;25(8):970-5. doi: 10.1097/CAD.0000000000000126. Anticancer Drugs. 2014. PMID: 24849707
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Fayette J, Fontaine-Delaruelle C, Ambrun A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J, Diallo A, Céruse P. Fayette J, et al. Among authors: poupart m. Oncotarget. 2016 Jun 14;7(24):37297-37304. doi: 10.18632/oncotarget.8934. Oncotarget. 2016. PMID: 27119503 Free PMC article.
Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P. Fayette J, et al. Among authors: poupart m. Drug Des Devel Ther. 2015 Nov 26;9:6203-10. doi: 10.2147/DDDT.S81488. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648696 Free PMC article.
90 results